Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders

The approval of ViroPharma/Lev's hereditary angioedema therapyCinryze on Oct. 10, with orphan status for prophylaxis only, leaves the window open for other C1 esterase inhibitors to claim the prize of orphan exclusivity for treatment of acute attacks. But ViroPharma thinks it can win that too